Progress in microRNA delivery.

siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12

The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol (2015) 1.03

Exosomes/miRNAs as mediating cell-based therapy of stroke. Front Cell Neurosci (2014) 1.03

MicroRNAs in metabolism. Acta Physiol (Oxf) (2016) 0.97

Non-coding RNAs and gastric cancer. World J Gastroenterol (2014) 0.96

microRNA therapies in cancer. Mol Cell Ther (2014) 0.95

Magnet-Bead Based MicroRNA Delivery System to Modify CD133(+) Stem Cells. Stem Cells Int (2016) 0.95

MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res (2014) 0.93

The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci (2015) 0.91

Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. J Neurosci (2014) 0.91

Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. ACS Nano (2015) 0.91

Detection of an Abundant Plant-Based Small RNA in Healthy Consumers. PLoS One (2015) 0.89

microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis. Adv Exp Med Biol (2015) 0.89

MicroRNA Targeting to Modulate Tumor Microenvironment. Front Oncol (2016) 0.86

miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem (2014) 0.84

MicroRNA Regulation of Human Breast Cancer Stem Cells. J Clin Med (2015) 0.84

microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget (2015) 0.84

MicroRNAs and their applications in kidney diseases. Pediatr Nephrol (2014) 0.84

E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis. Sci Rep (2016) 0.83

MicroRNA-mediated regulation of differentiation and trans-differentiation in stem cells. Adv Drug Deliv Rev (2015) 0.83

miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis. Oncotarget (2016) 0.83

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res (2015) 0.82

Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease. Mol Ther Nucleic Acids (2015) 0.82

Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy. J Control Release (2016) 0.81

Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness. Mol Pharm (2016) 0.81

Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther (2014) 0.81

MicroRNA and Heart Failure. Int J Mol Sci (2016) 0.81

Current Status and Strategy of microRNA Research for Cartilage Development and Osteoarthritis Pathogenesis. J Bone Metab (2016) 0.81

MicroRNAs in liver fibrosis: Focusing on the interaction with hedgehog signaling. World J Gastroenterol (2016) 0.80

Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential. Peptides (2014) 0.80

MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma. Oncotarget (2016) 0.80

Hijacking the Cellular Mail: Exosome Mediated Differentiation of Mesenchymal Stem Cells. Stem Cells Int (2016) 0.80

MicroRNAs in Cholangiopathies. Curr Pathobiol Rep (2014) 0.80

Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed Res Int (2014) 0.79

MicroRNA delivery for regenerative medicine. Adv Drug Deliv Rev (2015) 0.79

Bufalin promotes apoptosis of gastric cancer by down-regulation of miR-298 targeting bax. Int J Clin Exp Med (2015) 0.79

Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy. Genes Chromosomes Cancer (2015) 0.78

Micromanaging cardiac regeneration: Targeted delivery of microRNAs for cardiac repair and regeneration. World J Cardiol (2016) 0.78

Extracellular control of intracellular drug release for enhanced safety of anti-cancer chemotherapy. Sci Rep (2016) 0.78

MicroRNAs and benign biliary tract diseases. Semin Liver Dis (2015) 0.78

MiRNA-Target Interaction Reveals Cell-Specific Post-Transcriptional Regulation in Mammalian Cell Lines. Int J Mol Sci (2016) 0.78

Anti-microRNAs as Novel Therapeutic Agents in the Clinical Management of Alzheimer's Disease. Front Neurosci (2016) 0.77

The Role of miRNAs in Common Inflammatory Arthropathies: Osteoarthritis and Gouty Arthritis. Biomolecules (2016) 0.77

Concise review: new frontiers in microRNA-based tissue regeneration. Stem Cells Transl Med (2014) 0.77

MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown. J Hematol Oncol (2015) 0.77

Regulation of angiogenesis through the efficient delivery of microRNAs into endothelial cells using polyamine-coated carbon nanotubes. Nanomedicine (2016) 0.76

Regulatory functions and pathological relevance of the MECP2 3'UTR in the central nervous system. Cell Regen (Lond) (2015) 0.76

MicroRNAs in brain metastases: potential role as diagnostics and therapeutics. Int J Mol Sci (2014) 0.76

Nanoparticle delivery of miR-223 to attenuate macrophage fusion. Biomaterials (2016) 0.76

Targeting translesion synthesis to facilitate the eradication of ovarian cancer stem cells by platinum-based therapy. Mol Cell Oncol (2015) 0.76

BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cell Mol Life Sci (2017) 0.76

Development of switchable polymers to address the dilemma of stability and cargo release in polycationic nucleic acid carriers. Biomaterials (2017) 0.75

Therapeutic potential of microRNA: a new target to treat intrahepatic portal hypertension? Biomed Res Int (2014) 0.75

Developing miRNA therapeutics for cardiac repair in ischemic heart disease. J Thorac Dis (2016) 0.75

Intravenous Administration Is an Effective and Safe Route for Cancer Gene Therapy Using the Bifidobacterium-Mediated Recombinant HSV-1 Thymidine Kinase and Ganciclovir. Int J Mol Sci (2016) 0.75

Plant MicroRNAs-Novel Players in Natural Medicine? Int J Mol Sci (2016) 0.75

miRNA nanotherapeutics for cancer. Drug Discov Today (2016) 0.75

Folate-conjugated polyspermine for lung cancer-targeted gene therapy. Acta Pharm Sin B (2016) 0.75

Charged group surface accessibility determines micelleplexes formation and cellular interaction. Nanoscale (2015) 0.75

Pigmy MicroRNA: surveillance cops in Therapies kingdom. Mol Med (2016) 0.75

ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Cancer Sci (2016) 0.75

RNA interference-based nanosystems for inflammatory bowel disease therapy. Int J Nanomedicine (2016) 0.75

MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers. Front Pharmacol (2016) 0.75

MiRNA-27a promotes the proliferation and invasion of human gastric cancer MGC803 cells by targeting SFRP1 via Wnt/β-catenin signaling pathway. Am J Cancer Res (2017) 0.75

MiR-146a/b: a family with shared seeds and different roots. Physiol Genomics (2017) 0.75

The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p. RNA Dis (2016) 0.75

Nanoscale Extracellular Vesicle Analysis in Alzheimer's Disease Diagnosis and Therapy. Int J Alzheimers Dis (2016) 0.75

Oligonucleotides conjugated with short chemically defined polyethylene glycol chains are efficient antisense agents. Bioorg Med Chem Lett (2014) 0.75

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy. Expert Opin Drug Deliv (2016) 0.75

Roles of exosomes in the normal and diseased eye. Prog Retin Eye Res (2017) 0.75

The interplay of microRNAs and post-ischemic glutamate excitotoxicity: an emergent research field in stroke medicine. Neurol Sci (2016) 0.75

RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations. J Transl Med (2017) 0.75

Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Oncotarget (2017) 0.75

Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? Cancers (Basel) (2017) 0.75

Emerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic Agents. J Stroke (2017) 0.75

MicroRNAs and Periodontal Homeostasis. J Dent Res (2017) 0.75

MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

The functions of animal microRNAs. Nature (2004) 64.85

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62

Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95

The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature (2000) 39.31

MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83

The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 35.49

Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell (1993) 33.79

Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26

Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04

Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature (2000) 19.15

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16

The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol (1999) 17.82

Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17.64

Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84

siRNAs can function as miRNAs. Genes Dev (2003) 16.08

Processing of primary microRNAs by the Microprocessor complex. Nature (2004) 14.59

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods (2007) 13.94

Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46

LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30

miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature (2009) 10.26

Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02

Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91

A microRNA array reveals extensive regulation of microRNAs during brain development. RNA (2003) 9.76

Natural RNA circles function as efficient microRNA sponges. Nature (2013) 8.93

Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 8.63

Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA (2004) 8.31

MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res (2008) 7.53

Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18

MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67

Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59

Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 6.49

Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37

Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07

Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol (2009) 6.03

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67

RNA meets chromatin. Genes Dev (2005) 5.66

Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65

Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59

Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A (2007) 5.50

Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods (2004) 5.45

Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21

Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90

Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science (2007) 4.72

PEGylation, successful approach to drug delivery. Drug Discov Today (2005) 4.56

MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12

Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum (2008) 4.08

Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res (2007) 3.89

Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 3.85

RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70

Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol (2007) 3.67

Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol (2009) 3.66

MicroRNAs add a new dimension to cardiovascular disease. Circulation (2010) 3.64

Barriers to drug delivery in solid tumors. Sci Am (1994) 3.57

Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res (2003) 3.39

Silencing by small RNAs is linked to endosomal trafficking. Nat Cell Biol (2009) 3.25

The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One (2012) 3.14

Current status of polymeric gene delivery systems. Adv Drug Deliv Rev (2006) 3.04

Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A (2000) 3.04

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94

Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92

Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75

Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69

Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem (2004) 2.66

MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res (2009) 2.64

Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat Rev Mol Cell Biol (2011) 2.51

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30

Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28

Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther (2012) 2.15

The origins and evolution of "controlled" drug delivery systems. J Control Release (2008) 2.05

Chemical modification of siRNAs for in vivo use. Oligonucleotides (2008) 2.03

Peptide and protein PEGylation: a review of problems and solutions. Biomaterials (2001) 2.00

RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol (2004) 1.98

Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91

miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90

MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88

A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res (2009) 1.84

The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One (2011) 1.81

Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther (2010) 1.81

Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81

MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res (2011) 1.79

Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene (2007) 1.77

MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer (2010) 1.74

Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res (2004) 1.67

Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev (2006) 1.66

Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol (2006) 1.61

Peptide nucleic acids (PNA): synthesis, properties and potential applications. Bioorg Med Chem (1996) 1.58

Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release (2001) 1.51

Developing therapeutic microRNAs for cancer. Gene Ther (2011) 1.49

Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release (2013) 1.77

Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J Control Release (2005) 1.27

Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrixes. Bioconjug Chem (2005) 1.21

Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target (2007) 1.21

Effects of molecular weight and loading on matrix metalloproteinase-2 mediated release from poly(ethylene glycol) diacrylate hydrogels. AAPS J (2012) 1.12

In vitro evaluation of macroporous hydrogels to facilitate stem cell infiltration, growth, and mineralization. Tissue Eng Part A (2009) 1.09

Cellular alignment by grafted adhesion peptide surface density gradients. J Biomed Mater Res A (2004) 0.99

Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors. Mol Pharm (2011) 0.95

Improved cell adhesion and proliferation on synthetic phosphonic acid-containing hydrogels. Biomaterials (2005) 0.94

Matrix metalloprotease selective peptide substrates cleavage within hydrogel matrices for cancer chemotherapy activation. Peptides (2008) 0.92

Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur J Pharm Biopharm (2008) 0.92

Markers Are Shared Between Adipogenic and Osteogenic Differentiated Mesenchymal Stem Cells. J Dev Biol Tissue Eng (2013) 0.91

Decellularized human cornea for reconstructing the corneal epithelium and anterior stroma. Tissue Eng Part C Methods (2011) 0.90

Extracellular protease activation of chemotherapeutics from hydrogel matrices: a new paradigm for local chemotherapy. Mol Pharm (2005) 0.87

Cervical cancer treatment with a locally insertable controlled release delivery system. J Control Release (2006) 0.86

High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng (2015) 0.86

In vivo investigation of hybrid Paclitaxel nanocrystals with dual fluorescent probes for cancer theranostics. Pharm Res (2013) 0.85

Fabrication of Poly(ethylene glycol) Hydrogel Structures for Pharmaceutical Applications using Electron beam and Optical Lithography. J Vac Sci Technol B Microelectron Nanometer Struct Process Meas Phenom (2010) 0.84

Stem cell-derived extracellular matrix enables survival and multilineage differentiation within superporous hydrogels. Biomacromolecules (2012) 0.84

In vitro evaluation of functional interaction of integrin alphavbeta3 and matrix metalloprotease-2. Mol Pharm (2009) 0.83

Critical factors affecting cell encapsulation in superporous hydrogels. Biomed Mater (2012) 0.81

Initial evaluation of vascular ingrowth into superporous hydrogels. J Tissue Eng Regen Med (2009) 0.81

Development of amine-containing polymeric particles. J Biomater Sci Polym Ed (2005) 0.80

Improving matrix metalloproteinase-2 specific response of a hydrogel system using electrophoresis. Int J Pharm (2012) 0.80

Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential. Peptides (2014) 0.80

In-house preparation of hydrogels for batch affinity purification of glutathione S-transferase tagged recombinant proteins. BMC Biotechnol (2012) 0.79

Enhanced osteoblast-like cell adhesion and proliferation using sulfonate-bearing polymeric scaffolds. J Biomed Mater Res A (2007) 0.79

Proteolytically activated anti-bacterial hydrogel microspheres. J Control Release (2013) 0.78

Hybrid superporous scaffolds: an application for cornea tissue engineering. Crit Rev Biomed Eng (2008) 0.78

Activation of membrane receptors by neurotransmitter released from temperature-sensitive hydrogels. J Neurosci Methods (2005) 0.77

Active, soluble recombinant melittin purified by extracting insoluble lysate of Escherichia coli without denaturation. Biotechnol Prog (2013) 0.77

Assessment of a modular transfection system based upon cellular localization of DNA. Mol Pharm (2005) 0.76

Pharmacokinetics and treatment efficacy of camptothecin nanocrystals on lung metastasis. Mol Pharm (2013) 0.76

Stability of benzocaine formulated in commercial oral disintegrating tablet platforms. AAPS PharmSciTech (2013) 0.75

Hybrid nanocrystals: University of Kentucky US20060280680A1. Expert Opin Ther Pat (2012) 0.75

Charged group surface accessibility determines micelleplexes formation and cellular interaction. Nanoscale (2015) 0.75

Toroidal-spiral particles for codelivery of anti-VEGFR-2 antibody and irinotecan: a potential implant to hinder recurrence of glioblastoma multiforme. Biomacromolecules (2014) 0.75